



FROM THE EDITOR

Dear colleagues,

It is a pleasure to present you the first issue of our journal this year. We have a review, five research articles, and two case reports in this issue. The review is on nebulizer treatment in asthma attacks during the COVID-19 pandemic, which is in accordance with the fact that COVID is still the main item on the global agenda. The authors suggest using metered dose inhaler bronchodilators instead of nebulizers, unless nebulizer therapy is essential. When indicated, nebulizer therapy can be used by following the infection control recommendations. Chronic urticaria is one of the most common diseases seen in daily clinical allergy practice, and the first research article is on anxiety, depression, and quality of life in chronic urticaria patients. The second article is from a tertiary adult immunology referral center in our country and presents the analysis results of autoimmune diseases in a cohort of adult primary immune deficiency patients. The authors suggest that non-immunologist physicians should be aware of the association between autoimmune diseases and the underlying primary immune deficiency. The third article is on the relationship between obesity and childhood asthma. The authors conclude that central obesity is associated with asthma and its severity, but not with atopy. The fourth one is on the prevalence of allergic diseases in patients with common auto-inflammatory diseases. They have shown that allergic diseases were more common in patients with Familial Mediterranean Fever and Behçet's disease compared to those with other rheumatic diseases and the control group, although the atopy rate was similar in all groups. The fifth and last research article presents the results of the hearing assessment of adult common variable immunodeficiency patients, since they commonly present with acute and chronic sinusitis as well as otitis media. They concluded that this group of patients has an increased occurrence of conductive and sensorineural hearing loss. The first case report presents the management and successful desensitization of abatacept-induced anaphylaxis. The second one is on oculocutaneous albinism, type 7.

As the editorial team, we hope that this issue contributes to your daily clinical practice.

Yours Respectfully

Gül KARAKAYA

Editor